Non-Small Cell Lung Cancer clinical trials
Showing 551–600 of 711 active trials. Describe your situation to see which ones you may be eligible for.
- MYLUNG Consortium Part 3: Observational Study
- Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics
- I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
- Extracellular Vesicles and Particles (EVP) as Biomarkers of Recurrence in Non-Small Cell Lung Cancer
- Met Non Small Cell Cancer Registry (MOMENT)
- Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC
- GEMINI-NSCLC: NSCLC Biomarker Study
- Predictive Biomarkers for Pneumonitis After Chemoradiotherapy and Immunotherapy in Patients With Non-small Cell Lung Cancer
- Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients
- KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
- Longitudinal Evaluation of Microbial and Host Signatures During Immunotherapy for Lung Cancer
- Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.
- Biomarkers for Risk Stratification in Lung Cancer
- Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy
- Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
- Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers
- A Study of a New PET Scanner in People With Cancer
- LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
- SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
- Biology of Young Lung Cancer Study: The YOUNG LUNG Study
- PROSPECT - Profiling of Resistance Patterns & Oncogenic Signaling Pathways in Evaluation of Cancers of the Thorax and Therapeutic Target Identification
- Development and Analysis of a Stool Bank for Cancer Patients
- DNA Analysis of Blood and Tissue from Patients with Lung Cancer
- Lung Cancer Biomarkers and Screening
- Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
- Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Intratumoral N17350 in Advanced Solid Tumors
- A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
- A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
- A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
- Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies
- Pan-tumor MRD Study
- Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
- BostonGene and Exigent Genomic INsight Study
- DREAM: Double Lung Transplant REgistry Aimed for Lung-limited Malignancies
- Liquid Biopsy-informed Precision Oncology Study to Evaluate Utility of Plasma Genomic Profiling for Therapy Selection
- ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
- Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- A Multicenter Cancer Biospecimen Collection Study
- Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
- Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
- Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
- Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
- Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
- Preliminary Efficacy of Different Exercise Training During Immunotherapy in Patients With Lung Cancer: The ENHANCE Trial
- Prehabilitation Physical Therapy and Relaxation Intervention Program to Promote Resiliency and Operative Success Among Adults Receiving Lung Cancer Surgery, ROAR-LCS Trial
- Evaluation of Geriatric Assessment and Management for Older Adults With Non-small Cell Lung Cancer Receiving Chemotherapy Radiation Therapy
- Mobile Application to Improve Health-Related Outcomes in Patients With Advanced Lung Cancer
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.